EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

How effective are experienced hepatologists at staging fibrosis using non‐invasive fibrosis tests in patients with metabolic dysfunction‐associated steatotic liver disease?

Stuart McPherson iD, Jessica K Dyson, Laura Jopson, Steven Masson iD, Preya Patel, Quentin M Anstee iD

Alimentary Pharmacology & Therapeutics · 2024

DOI: 10.1111/apt.18061 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2024. Verfasst von Stuart McPherson und 5 weiteren Autor:innen. Beteiligte Einrichtung: Liver Unit, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Freeman Hospital, Newcastle upon Tyne, UK. Hauptthemen laut MEDLINE: Liver Cirrhosis, Elasticity Imaging Techniques. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Innovative Medicines Initiative (IMI2), European Union, EFPIA, Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Sequential use of non‐invasive fibrosis tests (NITs) to identify patients with advanced hepatic fibrosis is recommended. However, it remains unclear how reliable clinicians are staging liver fibrosis using combinations of NITs.

Aim

Our aim was to assess concordance between NIT‐based ‘clinician fibrosis assessment (CFA)’ and histology in patients with metabolic dysfunction‐associated steatotic liver disease (MASLD) and compare this with established algorithmic approaches.

Methods

Six experienced hepatologists independently staged 230 MASLD patients for advanced fibrosis (F0‐2 vs F3‐4) using FIB‐4, FIB‐4+ELF, FIB‐4+ vibration controlled transient elastography (VCTE; Fibroscan™) and FIB‐4+ELF+VTCE. Concordance between histology and CFA or algorithmic approaches were assessed.

Results

A total of 230 patients were included (median age 54 [22–78] years; 55% female; median FIB‐4 1.21 [IQR: 0.78–1.91]; ELF 9.3 [IQR: 8.6–10.2]; VCTE 9.4 [IQR: 6.3–14.3]; 41% F0‐1, 22% F2, 21% F3 and 16% F4). Overall, area under the receiver operator curves for histologic F3‐4 for the raw tests were 0.84 for FIB‐4, 0.86 for ELF and 0.86 for VCTE. Concordance between the hepatologists was good (FIB4, κ = 0.64; FIB‐4+ELF, κ = 0.70; FIB‐4+VCTE, κ = 0.69; FIB‐4+ELF+VCTE, κ = 0.70). Concordance between individual CFA and histology was variable, which was reflected in variability in sensitivity (44%–84%) and specificity (76%–94%). Concordance with histology was better when clinicians used NIT combinations. Purely algorithmic approaches, particularly sequential use of FIB‐4 then VCTE, tended to perform better than the CFA.

Conclusions

Adhering to the recommended algorithmic approaches using NITs to stage fibrosis tended to perform more accurately than less‐structured clinician NIT‐based assessments conducted by experienced hepatologists.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver CirrhosisElasticity Imaging TechniquesHumansFemaleMaleMiddle AgedAgedAdultSeverity of Illness IndexFatty LiverYoung AdultAlgorithmsBiopsyNon-alcoholic Fatty Liver DiseaseLiver

Autor:innen und Institutionen

  • Liver Unit, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Freeman Hospital, Newcastle upon Tyne, UK.
  • Newcastle NIHR Biomedical Research Centre, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
  • Translational & Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.

ORCID-Profile: Stuart McPherson, Steven Masson, Quentin M Anstee

Förderung

  • Innovative Medicines Initiative (IMI2), European Union
  • EFPIA
  • Medical Research Council
  • European Federation of Pharmaceutical Industries and Associations

Zitieren

APA

McPherson, S., Dyson, J. K., Jopson, L., Masson, S., Patel, P., & Anstee, Q. M. (2024). How effective are experienced hepatologists at staging fibrosis using non‐invasive fibrosis tests in patients with metabolic dysfunction‐associated steatotic liver disease?. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.18061

Vancouver

McPherson S, Dyson JK, Jopson L, Masson S, Patel P, Anstee QM. How effective are experienced hepatologists at staging fibrosis using non‐invasive fibrosis tests in patients with metabolic dysfunction‐associated steatotic liver disease?. Alimentary Pharmacology & Therapeutics. 2024. doi:10.1111/apt.18061

BibTeX
@article{McPherson2024,
  author = {McPherson, Stuart and Dyson, Jessica K and Jopson, Laura and Masson, Steven and Patel, Preya and Anstee, Quentin M},
  title = {How effective are experienced hepatologists at staging fibrosis using non‐invasive fibrosis tests in patients with metabolic dysfunction‐associated steatotic liver disease?},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2024},
  doi = {10.1111/apt.18061}
}
Kostenlos starten →